Cantor Fitzgerald Weighs in on COMPASS Pathways plc’s FY2022 Earnings (NASDAQ:CMPS)

COMPASS Pathways plc (NASDAQ:CMPSGet Rating) – Cantor Fitzgerald lifted their FY2022 EPS estimates for COMPASS Pathways in a research report issued to clients and investors on Wednesday, May 11th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will earn ($2.54) per share for the year, up from their previous estimate of ($3.02).

COMPASS Pathways (NASDAQ:CMPSGet Rating) last issued its earnings results on Tuesday, May 10th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.18. During the same period last year, the business posted ($0.35) earnings per share.

Several other research analysts have also commented on CMPS. Canaccord Genuity Group decreased their target price on COMPASS Pathways from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Monday, February 28th. Zacks Investment Research upgraded COMPASS Pathways from a “sell” rating to a “hold” rating in a research report on Monday, May 2nd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, COMPASS Pathways currently has an average rating of “Buy” and a consensus target price of $74.89.

Shares of CMPS opened at $7.06 on Friday. The stock has a 50 day moving average of $11.85 and a 200-day moving average of $19.95. COMPASS Pathways has a 52 week low of $6.54 and a 52 week high of $49.51.

In other COMPASS Pathways news, insider Ekaterina Malievskaia sold 6,372 shares of COMPASS Pathways stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $12.48, for a total transaction of $79,522.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David Y. Norton sold 3,384 shares of COMPASS Pathways stock in a transaction on Tuesday, March 29th. The shares were sold at an average price of $12.48, for a total value of $42,232.32. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in the business. AGF Investments Inc. raised its stake in COMPASS Pathways by 19.9% during the 1st quarter. AGF Investments Inc. now owns 1,200,000 shares of the company’s stock valued at $15,468,000 after acquiring an additional 199,268 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of COMPASS Pathways by 17.8% in the 1st quarter. Victory Capital Management Inc. now owns 898,714 shares of the company’s stock worth $11,585,000 after buying an additional 135,546 shares in the last quarter. BlackRock Inc. raised its stake in shares of COMPASS Pathways by 27.3% in the 1st quarter. BlackRock Inc. now owns 275,338 shares of the company’s stock worth $3,549,000 after buying an additional 59,018 shares in the last quarter. CQS US LLC bought a new stake in shares of COMPASS Pathways in the 4th quarter worth $5,945,000. Finally, Ghost Tree Capital LLC raised its stake in shares of COMPASS Pathways by 110.0% in the 4th quarter. Ghost Tree Capital LLC now owns 210,000 shares of the company’s stock worth $4,641,000 after buying an additional 110,000 shares in the last quarter. 17.86% of the stock is currently owned by hedge funds and other institutional investors.

About COMPASS Pathways (Get Rating)

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.

See Also

Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.